Tech Company Financing Transactions
OSE Immunotherapeutics Funding Round
On 4/10/2024, OSE Immunotherapeutics landed $8.9 million in financing from Bpifrance.
Transaction Overview
Company Name
Announced On
4/10/2024
Transaction Type
Venture Equity
Amount
$8,900,000
Round
Undisclosed
Investors
Proceeds Purpose
This public funding will support the registration Phase 3 clinical trial of neoepitope-based cancer vaccine Tedopi®, in second line treatment in HLA-A2 positive non-small cell lung patients with secondary (acquired) resistance to anti-PD-(L)1 immunotherapy.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
22, Boulevard Benoni Goullin
Nantes, 44200
FR
Nantes, 44200
FR
Phone
Website
Email Address
Overview
OSE Immunotherapeutics SA is a France-based biotechnology company focused on the development of immunotherapies for immune activation and regulation in the fields of immuno-oncology and autoimmune diseases. The product portfolio of the company comprises Tedopi, OSE-172, OSE-703, FR104 and OSE-127.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Dominique Costantini
Chairman
Maryvonne Hiance
Chief Executive Officer
Nicolas Poirier
Browse more venture capital transactions:
Prev: 4/10/2024: Collaborative Robotics venture capital transaction
Next: 4/10/2024: Corlytics venture capital transaction
Share this article
Where The Data Comes From
We do our best to record funding rounds that are announced publicly. VC transactions on this site are sourced from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs